Spectral Diagnostics (OTCMKTS:EDTXF) Stock Price Up 3% – Still a Buy?

Spectral Diagnostics Inc. (OTCMKTS:EDTXF)’s stock price traded up 3% during trading on Friday . The stock traded as high as $1.0505 and last traded at $1.03. 6,980 shares traded hands during trading, a decline of 48% from the average session volume of 13,372 shares. The stock had previously closed at $1.00.

Spectral Diagnostics Stock Performance

The company has a fifty day moving average price of $0.97 and a two-hundred day moving average price of $0.91. The company has a market cap of $301.33 million, a P/E ratio of -9.36 and a beta of 0.07.

Spectral Diagnostics (OTCMKTS:EDTXF) last released its earnings results on Friday, November 7th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.07). The company had revenue of $0.49 million during the quarter, compared to analyst estimates of $0.54 million.

About Spectral Diagnostics

Spectral Medical Inc focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies.